2017

• Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously negotiated royalty rates on aducanumab. Moreover, Neurimmune will receive an additional one-time $50 million payment subject to Biogen’s exercise of an option for an additional 5% royalty buy-down.

2016

• Heptares acquires G7 Therapeutics for CHF 12 million.
• Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company.
• Topadur Pharma AG wins Swiss Technology Award 2016 in the category Start-up.
• Aducanumab, the antibody developed jointly by the University of Zurich, Neurimmune und Biogen, leads to a considerable reduction in harmful beta-amyloid plaques in patients with early forms of Alzheimer’s. As part of a clinical phase Ib trial, treatment with the antibody over a one-year period made the beta-amyloid plaques in the patients’ brains disappear almost completely. The results were published in the prestigious journal Nature.
• Cell Medica, a leader in the development, manufacturing, and marketing of cellular therapeutics to treat cancer and viral infections, acquires Delenex Therapeutics.
• In Stockholm, NeMoDevices AG receives the Eurostars Innovation Award for the project “Opto-Brain”, which is deemed to be the best of a thousand Eurostar projects.
• Cytos Biotechnology AG merges with the Zurich-based company, Kuros Biosurgery Holding AG, and is renamed Kuros Biosciences AG.

2015

• Neurimmune receives major US$60 million development milestone upon initiation of global phase 3 studies with Aducanumab for early Alzheimer’s disease.
• InSphero AG secures CHF 20 million series C financing.
• GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid $190 million to purchase the remaining stake in the company, which is valued at $212 million in total.
• Pfizer acquires Redvax GmbH, a Swiss biopharmaceutical company that is a spin-off from Redbiotec AG.

2014

• Total offer size of Molecular Partner’s IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option.
• FierceBiotech names Molecular Partners as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
• 100 experts vote for InSphero as the best Swiss Start-up.
• Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson acquires Covagen AG, an ETH spin-off specializing in the development of multi-specific protein therapeutics through the FynomAb^® technology platform.
• Thermo Fisher Scientific expands animal diagnostics business through acquisition of Prionics AG.